

PTI, April 2008

NEW DELHI: Claris Life sciences on Tuesday said it has received US food and drug administration (USFDA) nod for selling three different injectable products in the US market.

Ahmedabad-based company has got the approval from USFDA for selling Ciproflaxacin and Metronidazole, the anti-infective compounds and Ondansetron, an anti-vomiting drug in the US market.

The successful launch of these products in the market would provide a major fillip to the company's US strategy and overall business growth, the company said in a statement.

Claris is an international Life science company operating in critical care segment, with special focus on injectables. - PTI

- April 2008